Alterity Therapeutics (ATHE) Invested Capital (2011 - 2025)

Alterity Therapeutics' Invested Capital history runs 13 years deep, the most recent figure standing at -$1.7 million for Q2 2025.

• On a quarterly basis, Invested Capital rose 45.61% year-over-year to -$1.7 million in Q2 2025; TTM through Dec 2025 was -$5.0 million, a 13.01% increase from a year earlier, with the FY2025 full-year figure at -$1.7 million, up 45.61% from the prior year.
• Invested Capital advanced to -$1.7 million in Q2 2025 per ATHE's latest filing, from -$3.2 million in the prior quarter.
• Across five years, Invested Capital topped out at -$1.7 million in Q2 2025 and bottomed at -$3.7 million in Q2 2022.
• The 5-year median for Invested Capital is -$2.5 million (2023), against an average of -$2.6 million.
• Across the five-year window, Invested Capital sank 89.21% in 2022 and jumped 45.61% in 2025, its largest moves.
• Year by year, Invested Capital stood at -$2.0 million in 2021, then sank by 89.21% to -$3.7 million in 2022, then surged by 33.41% to -$2.5 million in 2023, then decreased by 29.04% to -$3.2 million in 2024, then surged by 45.61% to -$1.7 million in 2025.
• Per Business Quant, the three latest ATHE Invested Capital figures stand at -$1.7 million (Q2 2025), -$3.2 million (Q2 2024), and -$2.5 million (Q2 2023).